MedTrace Logo

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

NCT01468467 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-02-12

No results posted yet for this study

Summary

The purpose of this study is to define a safe dose of AC220 when given as maintenance therapy after treatment with an allogeneic stem cell transplant.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

DRUG

AC220

Oral Liquid

Sponsors & Collaborators

  • Ambit Biosciences Corporation

    collaborator INDUSTRY

  • Daiichi Sankyo

    lead INDUSTRY

Principal Investigators

  • Guy Gammon, MB, BS, MRCP · Medical Monitor, Ambit Biosciences Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468467 on ClinicalTrials.gov